Brief: KYORIN Holdings unit gets license from Merck for drug KRP-114V

Kyorin Pharmaceutical

11/04/2017 06:54

April 11 (Reuters) - KYORIN Holdings Inc  4569.T  : 
     
    * Says its pharma unit receives license from US firm Merck & 
Co Inc for drug KRP-114V, a treatment for overactive bladder, 
owning exclusive rights to develop and commercialize in Asian 
area 
     
    Source text in Japanese: https://goo.gl/xXFk5L 
    Further company coverage: 4569.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 62674724; 
Reuters Messaging: Cheng.Li@thomsonreuters.com@reuters.net))